Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer (Q35681990)

9 August 2017

title

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

C F Jehn

1

1 reference

9 August 2017

L Böning

2

1 reference

9 August 2017

H Kröning

3

1 reference

9 August 2017

K Possinger

4

1 reference

9 August 2017

D Lüftner

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

3 January 2012

1 reference

British Journal of Cancer

9 August 2017

published in

1 reference

9 August 2017

volume

106

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

274-278

1 reference

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Comparing antibody and small-molecule therapies for cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261677

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia

12 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

Participation of patients 65 years of age or older in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.554

Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22215062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22215062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22215062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.554

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference